首页 > 最新文献

The British journal of clinical practice最新文献

英文 中文
A study to investigate the comparative efficacy and tolerability of nisoldipine coat-core and atenolol in the treatment of mild to moderate hypertension. 尼索地平包芯与阿替洛尔治疗轻中度高血压的疗效和耐受性比较研究。
T S Murray

The efficacy and tolerability of nisoldipine coat-core (nisoldipine CC 10, 20, 40 mg) and atenolol (50, 100 mg) were compared in 230 patients with mild to moderate essential hypertension. Treatment was titrated at two-weekly intervals as necessary to control blood pressure. After eight weeks of active therapy, the two treatments proved to be equally effective in reducing sitting diastolic blood pressure (13.7 +/- 8.3 mmHg and 14.2 +/- 9.1 mmHg for nisoldipine CC and atenolol, respectively), and provided equivalent reduction in systolic blood pressure and identical response rates (69%). Heart rate was reduced from baseline in the atenolol group but remained unchanged in the nisoldipine CC group (p < 0.001 difference between the two groups). Both nisoldipine CC and atenolol were well tolerated and had no detectable metabolic effects. Adverse events were minor and of the type commonly associated with drugs of these classes.

在230例轻中度原发性高血压患者中,比较尼索地平包芯(尼索地平CC 10、20、40 mg)和阿替洛尔(50、100 mg)的疗效和耐受性。治疗每两周滴定一次,以控制血压。经过8周的积极治疗,两种治疗方法在降低坐位舒张压方面同样有效(尼索地平CC和阿替洛尔分别为13.7 +/- 8.3 mmHg和14.2 +/- 9.1 mmHg),并提供相同的收缩压降低和相同的缓解率(69%)。阿替洛尔组心率较基线有所降低,但尼索地平CC组保持不变(两组差异p < 0.001)。尼索地平CC和阿替洛尔耐受性良好,没有可检测到的代谢影响。不良事件是轻微的,通常与这类药物相关的类型。
{"title":"A study to investigate the comparative efficacy and tolerability of nisoldipine coat-core and atenolol in the treatment of mild to moderate hypertension.","authors":"T S Murray","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The efficacy and tolerability of nisoldipine coat-core (nisoldipine CC 10, 20, 40 mg) and atenolol (50, 100 mg) were compared in 230 patients with mild to moderate essential hypertension. Treatment was titrated at two-weekly intervals as necessary to control blood pressure. After eight weeks of active therapy, the two treatments proved to be equally effective in reducing sitting diastolic blood pressure (13.7 +/- 8.3 mmHg and 14.2 +/- 9.1 mmHg for nisoldipine CC and atenolol, respectively), and provided equivalent reduction in systolic blood pressure and identical response rates (69%). Heart rate was reduced from baseline in the atenolol group but remained unchanged in the nisoldipine CC group (p < 0.001 difference between the two groups). Both nisoldipine CC and atenolol were well tolerated and had no detectable metabolic effects. Adverse events were minor and of the type commonly associated with drugs of these classes.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"368-72"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19975177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cough mixture induced psychosis. 咳嗽合剂诱发精神病。
D T Lee, L C Lam, K P Chan, H C Leung

Cough mixture is the third most commonly abused substance in Hong Kong. Over the last two years, ten cases of cough mixture-induced psychosis were admitted to a University hospital. All of them were clinically indistinguishable from paranoid schizophrenia, but the psychotic symptoms often resolved promptly with the cessation of cough mixture use or a small dose of haloperidol. A representative case is described. The possible underlying aetiological mechanism and the treatment principle are discussed.

止咳合剂是香港第三大最常滥用的药物。在过去的两年中,有10例咳嗽合剂引起的精神病被送入大学医院。所有患者在临床上与偏执型精神分裂症难以区分,但精神病症状往往在停止使用咳嗽合剂或小剂量氟哌啶醇后迅速消退。描述了一个典型案例。讨论了可能的病因机制和治疗原则。
{"title":"Cough mixture induced psychosis.","authors":"D T Lee,&nbsp;L C Lam,&nbsp;K P Chan,&nbsp;H C Leung","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cough mixture is the third most commonly abused substance in Hong Kong. Over the last two years, ten cases of cough mixture-induced psychosis were admitted to a University hospital. All of them were clinically indistinguishable from paranoid schizophrenia, but the psychotic symptoms often resolved promptly with the cessation of cough mixture use or a small dose of haloperidol. A representative case is described. The possible underlying aetiological mechanism and the treatment principle are discussed.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"400-1"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19976297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoephedrine toxicity in renal failure. 伪麻黄碱对肾功能衰竭的毒性。
C C Lyon, J H Turney

A case of pseudoephedrine toxicity is reported in a man with chronic renal failure. The effects of renal impairment on the metabolism of pseudoephedrine are discussed and the implications of the widespread availability of the drug in proprietary cold remedies are highlighted.

一例伪麻黄碱毒性报告在一个人与慢性肾功能衰竭。肾脏损害对伪麻黄碱代谢的影响进行了讨论,并强调了该药物在专有感冒药中的广泛可用性的含义。
{"title":"Pseudoephedrine toxicity in renal failure.","authors":"C C Lyon,&nbsp;J H Turney","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A case of pseudoephedrine toxicity is reported in a man with chronic renal failure. The effects of renal impairment on the metabolism of pseudoephedrine are discussed and the implications of the widespread availability of the drug in proprietary cold remedies are highlighted.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"396-7"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19976298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ruptured diaphragm: the latent phase. 隔膜破裂:潜伏期。
A M Huggon, A Houghton, D P Watson

Traumatic rupture of the diaphragm is an uncommon injury which can be missed unless there is a high index of suspicion. In the interval between rupture of the diaphragm and herniation of abdominal contents, signs and symptoms are nonspecific and the chest X-ray may be normal.

外伤性横膈膜破裂是一种罕见的损伤,除非有很高的怀疑指数,否则可能会被遗漏。在横膈膜破裂和腹部内容物突出之间,体征和症状无特异性,胸部x线检查可能正常。
{"title":"Ruptured diaphragm: the latent phase.","authors":"A M Huggon,&nbsp;A Houghton,&nbsp;D P Watson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Traumatic rupture of the diaphragm is an uncommon injury which can be missed unless there is a high index of suspicion. In the interval between rupture of the diaphragm and herniation of abdominal contents, signs and symptoms are nonspecific and the chest X-ray may be normal.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"408-9"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19976305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Instant lithium monitoring: a clinical revolution in the making. 即时锂监测:一场正在酝酿中的临床革命。
D P Srinivasan, N J Birch

The recent availability of portable ion selective electrodes (ISE) for clinical applications has enabled lithium estimations to be performed instantly and at close proximity to patients. The significance of this is, not in the accuracy of the determination, but in the speed of the feedback provided to doctor and patient, and hence the promotion of compliance. The impact of this on lithium therapy can only be described as a clinical revolution in the making.

最近用于临床应用的便携式离子选择电极(ISE)的可用性使得锂离子的估计能够在患者附近即时进行。其意义不在于测定的准确性,而在于向医生和患者提供反馈的速度,从而促进了依从性。这对锂治疗的影响只能被描述为一场正在酝酿中的临床革命。
{"title":"Instant lithium monitoring: a clinical revolution in the making.","authors":"D P Srinivasan,&nbsp;N J Birch","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The recent availability of portable ion selective electrodes (ISE) for clinical applications has enabled lithium estimations to be performed instantly and at close proximity to patients. The significance of this is, not in the accuracy of the determination, but in the speed of the feedback provided to doctor and patient, and hence the promotion of compliance. The impact of this on lithium therapy can only be described as a clinical revolution in the making.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"386-8"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19975180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lansoprazole plus clarithromycin: evaluation of a new dual therapy for Helicobacter pylori eradication. 兰索拉唑加克拉霉素:一种新的根除幽门螺杆菌双重疗法的评价。
P S Phull, A B Price, D Halliday, M R Jacyna

The aim of this pilot study was to evaluate the efficacy and safety of lansoprazole plus clarithromycin for eradication of Helicobacter pylori. A total of 26 patients with H. pylori infection were randomised to receive clarithromycin, 500 mg t.i.d. for 14 days, plus either lansoprazole, 30 mg o.m., (group L30, n = 13) or lansoprazole, 30 mg b.i.d., (group L60, n = 13). H. pylori status was determined pre-treatment and four to six weeks after completion of the study medication by histology and 13C-urea breath test. Two patients were unable to complete the course of medication. Of the remaining 24 patients, 14 (58%) successfully eradicated H. pylori--8/12 (67%) patients in group L30 and 6/12 (50%) in group L60. Side-effects were experienced by 17/26 (65%) of patients, most commonly a taste disturbance. The results from this pilot study suggest that dual therapy with lansoprazole plus clarithromycin is only a moderately effective regimen for eradicating H. pylori.

本初步研究的目的是评估兰索拉唑联合克拉霉素根除幽门螺杆菌的有效性和安全性。共有26例幽门螺旋杆菌感染患者随机接受克拉霉素治疗,每日500 mg,连续14天,加上兰索拉唑,每日30 mg, (L30组,n = 13)或兰索拉唑,每日30 mg, (L60组,n = 13)。通过组织学和13c -尿素呼气试验测定治疗前和研究用药结束后4 ~ 6周幽门螺杆菌状态。两名患者无法完成疗程。其余24例患者中,14例(58%)成功根除幽门螺杆菌,其中L30组8/12例(67%),L60组6/12例(50%)。17/26(65%)的患者出现了副作用,最常见的是味觉障碍。这项初步研究的结果表明,兰索拉唑加克拉霉素的双重治疗对于根除幽门螺杆菌仅是一种中等有效的方案。
{"title":"Lansoprazole plus clarithromycin: evaluation of a new dual therapy for Helicobacter pylori eradication.","authors":"P S Phull,&nbsp;A B Price,&nbsp;D Halliday,&nbsp;M R Jacyna","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this pilot study was to evaluate the efficacy and safety of lansoprazole plus clarithromycin for eradication of Helicobacter pylori. A total of 26 patients with H. pylori infection were randomised to receive clarithromycin, 500 mg t.i.d. for 14 days, plus either lansoprazole, 30 mg o.m., (group L30, n = 13) or lansoprazole, 30 mg b.i.d., (group L60, n = 13). H. pylori status was determined pre-treatment and four to six weeks after completion of the study medication by histology and 13C-urea breath test. Two patients were unable to complete the course of medication. Of the remaining 24 patients, 14 (58%) successfully eradicated H. pylori--8/12 (67%) patients in group L30 and 6/12 (50%) in group L60. Side-effects were experienced by 17/26 (65%) of patients, most commonly a taste disturbance. The results from this pilot study suggest that dual therapy with lansoprazole plus clarithromycin is only a moderately effective regimen for eradicating H. pylori.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"360-2"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19975176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A post-marketing surveillance study of Voltarol 75 mg SR in the primary care setting. Voltarol 75mg SR在初级保健机构的上市后监测研究。
C W Jones

A total of 7438 patients suffering from a wide variety of painful conditions was included in the final analysis of a post-marketing surveillance (PMS) study monitoring the use of Voltarol 75 mg SR in a primary care setting. Follow-up data were collected at visits conducted one, four and 12 months after the initial consultation. Improvement of symptoms was the most common reason for discontinuation of treatment (47% of patients who discontinued). Adverse events led to the withdrawal of 18% of patients overall. The rate of serious gastrointestinal complications was low (0.4%) and deleterious hepatic or renal effects were not apparent. There were significantly more events experienced by female patients and there was a significant effect of age on severe gastrointestinal events. In this PMS study Voltarol 75 mg SR was used successfully once or twice daily without any unexpected adverse effects in a manner consistent with current recommendations for the use of non-steroidal anti-inflammatory drugs.

共有7438名患有各种疼痛状况的患者被纳入了一项上市后监测(PMS)研究的最终分析,该研究监测了初级保健机构使用Voltarol 75mg SR的情况。在初次咨询后1个月、4个月和12个月的访问中收集随访数据。症状改善是停止治疗的最常见原因(47%的患者停止治疗)。总的来说,不良事件导致18%的患者停药。严重胃肠道并发症发生率低(0.4%),肝、肾损害不明显。女性患者经历的严重胃肠道事件明显更多,年龄对严重胃肠道事件有显著影响。在本经前症候群研究中,Voltarol 75mg SR每日成功使用1 - 2次,未出现任何意想不到的不良反应,与目前使用非甾体类抗炎药的建议一致。
{"title":"A post-marketing surveillance study of Voltarol 75 mg SR in the primary care setting.","authors":"C W Jones","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A total of 7438 patients suffering from a wide variety of painful conditions was included in the final analysis of a post-marketing surveillance (PMS) study monitoring the use of Voltarol 75 mg SR in a primary care setting. Follow-up data were collected at visits conducted one, four and 12 months after the initial consultation. Improvement of symptoms was the most common reason for discontinuation of treatment (47% of patients who discontinued). Adverse events led to the withdrawal of 18% of patients overall. The rate of serious gastrointestinal complications was low (0.4%) and deleterious hepatic or renal effects were not apparent. There were significantly more events experienced by female patients and there was a significant effect of age on severe gastrointestinal events. In this PMS study Voltarol 75 mg SR was used successfully once or twice daily without any unexpected adverse effects in a manner consistent with current recommendations for the use of non-steroidal anti-inflammatory drugs.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"390-5"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19975182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study. 降钙素治疗反射性交感神经营养不良的初步研究。
N Hamamci, E Dursun, C Ural, A Cakci

Reflex sympathetic dystrophy is one of the important complications effecting the rehabilitation programmes of hemiplegic patients in a negative manner by causing pain and function loss. In this study, the aim was to investigate the effects of salmon calcitonin treatment in reflex sympathetic dystrophy that develops in hemiplegia. Forty-one patients with hemiplegia resulting from cerebrovascular events and stage 1-2 reflex sympathetic dystrophy were included in the study. Salmon calcitonin, 1 x 100 IU/day intramuscularly for 4 weeks, was administered to 25 of these patients (calcitonin group) to the other 16 patients physiological saline, 1 ml/day intramuscularly for 4 weeks, was administered (control group). At the end of the fourth week of treatment the pain score of the calcitonin group was significantly lower than that of the control group. Shoulder abduction and external rotation, wrist flexion and metacarpophalangeal extension of the calcitonin group were found to be significantly better than those of the control group. In the calcitonin group the significant decrease in pain and tenderness resulted in improvement of range of motion and motor functions.

反射性交感神经营养不良是影响偏瘫患者康复计划的重要并发症之一,它引起疼痛和功能丧失。在这项研究中,目的是研究鲑鱼降钙素治疗在偏瘫中发展的反射性交感神经营养不良的效果。41例由脑血管事件和1-2期反射性交感神经营养不良引起的偏瘫患者被纳入研究。其中25例患者(降钙素组)给予鲑鱼降钙素,1 × 100 IU/天肌注,连续4周;另外16例患者给予生理盐水,1 ml/天肌注,连续4周(对照组)。治疗第4周结束时,降钙素组疼痛评分明显低于对照组。降钙素组肩关节外展和外旋、腕关节屈曲和掌指关节伸展均明显优于对照组。在降钙素组中,疼痛和压痛的显著减少导致运动范围和运动功能的改善。
{"title":"Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study.","authors":"N Hamamci,&nbsp;E Dursun,&nbsp;C Ural,&nbsp;A Cakci","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Reflex sympathetic dystrophy is one of the important complications effecting the rehabilitation programmes of hemiplegic patients in a negative manner by causing pain and function loss. In this study, the aim was to investigate the effects of salmon calcitonin treatment in reflex sympathetic dystrophy that develops in hemiplegia. Forty-one patients with hemiplegia resulting from cerebrovascular events and stage 1-2 reflex sympathetic dystrophy were included in the study. Salmon calcitonin, 1 x 100 IU/day intramuscularly for 4 weeks, was administered to 25 of these patients (calcitonin group) to the other 16 patients physiological saline, 1 ml/day intramuscularly for 4 weeks, was administered (control group). At the end of the fourth week of treatment the pain score of the calcitonin group was significantly lower than that of the control group. Shoulder abduction and external rotation, wrist flexion and metacarpophalangeal extension of the calcitonin group were found to be significantly better than those of the control group. In the calcitonin group the significant decrease in pain and tenderness resulted in improvement of range of motion and motor functions.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"373-5"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19975183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac tamponade in a 21-year-old body builder with anabolica abuse. 心脏填塞,21岁健身者滥用合成代谢。
M Roeggia, G Heinz, E Werba, G Roeggla
{"title":"Cardiac tamponade in a 21-year-old body builder with anabolica abuse.","authors":"M Roeggia,&nbsp;G Heinz,&nbsp;E Werba,&nbsp;G Roeggla","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"411-2"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19976306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis: a 12 month study. 布地奈德鼻内与二丙酸倍氯米松治疗常年性非过敏性鼻炎的临床比较:一项为期12个月的研究。
B Synnerstad, N Lindqvist

To evaluate possible differences in efficacy and safety between budesonide and beclomethasone dipropionate when used intranasally in the treatment of perennial non-allergic rhinitis, a 12-month open study was undertaken in 24 patients suffering from perennial non-allergic rhinitis. Both drugs were applied intranasally from pressurised aerosols at a daily dosage of 400 micrograms. On entry and at visits after 1, 2, 4, 6, 9 and 12 months, rhinoscopy was performed and the severity of nasal symptoms graded according to a four-point rating scale. All nasal symptoms were reduced from baseline during the treatment period in both groups. Tachyphylaxis was not observed. No clinically significant changes in haematology or blood chemistry parameters were observed in either group, and analysis of plasma cortisol levels revealed no influence of either drug on the hypothalamic-pituitary-adrenal axis. Local adverse reactions were uncommon and mild. Budesonide and beclomethasone dipropionate used intranasally at 400 micrograms per day were found to be safe, and budesonide was found to have a significantly higher (p < 0.05) efficacy than beclomethasone dipropionate in alleviating symptoms of perennial non-allergic rhinitis.

为了评估布地奈德和二丙酸倍氯米松鼻内治疗常年性非变应性鼻炎的疗效和安全性可能存在的差异,对24例常年性非变应性鼻炎患者进行了为期12个月的开放研究。这两种药物都是通过加压气雾剂鼻内施用,每日剂量为400微克。在入院时和1、2、4、6、9和12个月后就诊时,进行鼻镜检查,并根据四分制对鼻症状的严重程度进行分级。在治疗期间,两组患者的鼻部症状均较基线有所减轻。未观察到快速反应。两组患者的血液学或血液化学参数均未见临床显著变化,血浆皮质醇水平分析显示两种药物均未对下丘脑-垂体-肾上腺轴产生影响。局部不良反应罕见且轻微。布地奈德与二丙酸倍氯米松每天鼻内使用400微克是安全的,并且布地奈德在缓解常年性非变应性鼻炎症状方面的疗效显著高于二丙酸倍氯米松(p < 0.05)。
{"title":"A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis: a 12 month study.","authors":"B Synnerstad,&nbsp;N Lindqvist","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To evaluate possible differences in efficacy and safety between budesonide and beclomethasone dipropionate when used intranasally in the treatment of perennial non-allergic rhinitis, a 12-month open study was undertaken in 24 patients suffering from perennial non-allergic rhinitis. Both drugs were applied intranasally from pressurised aerosols at a daily dosage of 400 micrograms. On entry and at visits after 1, 2, 4, 6, 9 and 12 months, rhinoscopy was performed and the severity of nasal symptoms graded according to a four-point rating scale. All nasal symptoms were reduced from baseline during the treatment period in both groups. Tachyphylaxis was not observed. No clinically significant changes in haematology or blood chemistry parameters were observed in either group, and analysis of plasma cortisol levels revealed no influence of either drug on the hypothalamic-pituitary-adrenal axis. Local adverse reactions were uncommon and mild. Budesonide and beclomethasone dipropionate used intranasally at 400 micrograms per day were found to be safe, and budesonide was found to have a significantly higher (p < 0.05) efficacy than beclomethasone dipropionate in alleviating symptoms of perennial non-allergic rhinitis.</p>","PeriodicalId":22312,"journal":{"name":"The British journal of clinical practice","volume":"50 7","pages":"363-6"},"PeriodicalIF":0.0,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19975181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The British journal of clinical practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1